主要演讲
John Reynders, Ph.D., Vice President & Chief Information Officer, Johnson & Johnson, Pharma R&D
John leads the global R&D IT strategy across Pharma R&D operating companies, Global Development Organizations (GDOs) and Medical Affairs groups. John was most recently Information Officer, Lilly Research Laboratories, where he was responsible for Discovery and Development Informatics Systems for Eli Lilly and Company. As such, he successfully led IT across the North America, Europe, and Asia-Pacific organizations, increasing agility through organizational transformation, greater transparency through detailed portfolio and project management discipline, improved business alignment through balanced scorecard deployment, and more rapid execution through capabilities development. Prior to this, he was the Vice President of Informatics at Celera Genomics, where he formed its first Informatics division that integrated computational chemistry, computational biology, genetics, computer science, and software engineering - as well as enabling Celera's proprietary genomic, proteomic, and diagnostic platforms across therapeutic programs-to accelerate the company's large- and small-molecule portfolio. Before this, John held increasing positions of responsibility at Sun Microsystems and Los Alamos National Laboratories. He holds a Ph.D. in Applied and Computational Mathematics from Princeton University, as well as a Bachelor of Science in Mathematics, Summa Cum Laude, and a Physics Minor, Concentration in Fluid Mechanics, from Rensselaer Polytechnic Institute. He is currently working toward his Master of Business Administration at the Kellogg School of Business at Northwestern University. He holds multiple patents and honors, is a member of several professional societies and is the author of several papers.
Joshua Boger, Ph.D., President & Chief Executive Officer, Vertex Pharmaceuticals, Inc.
Dr. Joshua Boger is the founder, President and Chief Executive Officer of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Prior to founding Vertex in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, N.J., where he headed both the Departments of Biophysical Chemistry and Medicinal Chemistry of Immunology & Inflammation. During his ten years at Merck, Dr. Boger developed an international reputation as a leader in the application of computer modeling to the chemistry of drug design and was a pioneer in the use of structure-based rational drug design as the basis for drug discovery programs.
Dr. Boger holds a bachelor of arts in Chemistry and Philosophy from Wesleyan University (Connecticut) and a master's and doctorate degrees in Chemistry from Harvard University. His postdoctoral research in molecular recognition was performed in the laboratories of the Nobel-prize winning chemist, Jean-Marie Lehn in Strasbourg, France. He is the author of over 50 scientific publications, holds 31 issued U.S. patents in pharmaceutical discovery and development, and has lectured widely in the United States, in Europe and in Asia on various aspects of drug discovery and development. He was named one of forty Technology Pioneers worldwide for the 2003 World Economic Forum in Davos, Switzerland.
Dr. Boger is a Trustee of Wesleyan University (Middletown, CT), the Chairman of the Biotechnology Industry Organization (BIO), a founding Director of the New England Healthcare Institute (a non-profit, healthcare-policy research organization based in Cambridge, MA) and a Director of the Hastings Center (the leading independent bioethics research institute, located in Garrison, NY).
Linda Avey, co-Founder, 23andMe, Inc.
Linda has over 20 years of sales and business development experience in the biopharmaceutical industry in San Francisco, Boston, San Diego, and Washington, D.C. Prior to starting 23andMe, she developed translational research collaborations with academic and pharmaceutical partners for Affymetrix and Perlegen Sciences. Linda also spent time at Spotfire helping scientists understand the power of data visualization and at Applied Biosystems during the early days of the human genome project. The advent of high density genome-wide scanning technologies brought huge potential for significant discoveries. However, the lack of sufficient funding to enable adequate studies prompted Linda to think of a new research model. These ideas led to the formation of 23andMe. Her primary interest is the acceleration of personalized medicine, using genetic profiles to target the right drug to the right person at the correct dose. Linda graduated from Augustana College with a B.A. in biology.